The DESyne BDS Plus RCT: A Randomized Clinical Trial to Assess the Elixir DESyne BDS Plus Drug Eluting Coronary Stent System for the Treatment of de Novo Native Coronary Artery Lesions
A phase 2 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 200 participants.
Also called NCT05033964
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; single masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 200 participants
- Sponsor
- Registry
-
NCT05033964
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (anticipated)
- Countries
- Belgium, Brazil, Czechia, Netherlands, New Zealand
- Registry status
- Unknown status
Technical summary
Registry record NCT05033964. Randomized; single masking; primary purpose treatment. Start 2021-12-15 (actual); primary completion 2022-12-02 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- The DESyne BDS Plus RCT: A Randomized Clinical Trial to Assess the Elixir DESyne BDS Plus Drug Eluting Coronary Stent System for the Treatment of de Novo Native Coronary Artery Lesions
- Condition
- Coronary Artery Disease
- Intervention (Combination product)
- Percutaneous Coronary Intervention with drug eluting stents
- Lead sponsor
- Elixir Medical Corporation
Record details
- Record id
cardio:ct-nct05033964- Content hash
a8122b74620c75e264d8edfca692f117419df217ec34208a2dbd54f9c5eccc93